Sunshine Noah licenses hypertension siRNA drug ABA001 to Wangao Pharma for 50 million yuan
Sunshine Noah (688621.SH) licensed its Phase I siRNA hypertension drug ABA001 to Jiangsu Wangao Pharmaceutical. Wangao will invest 50 million yuan to fund domestic clinical trials, R&D, and regulatory filings, securing exclusive commercialization rights in China. The drug targets angiotensinogen mRNA for long-acting blood pressure control.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both sides agree that the 50 million yuan upfront is an option fee, not a full valuation of the drug.
- Both recognize that Wanguo's hospital distribution network is valuable for market access.
- Both acknowledge that the deal builds some manufacturing and clinical trial infrastructure for siRNA in China.
Points of contention
- Eastern Agent sees the deal as a strategic step toward China's pharmaceutical sovereignty, while Neutral Agent views it as a cautious, risk-hedging bet on unproven science.
- Eastern Agent argues that applying siRNA to hypertension is innovative adaptation, but Neutral Agent says it's just using a foreign platform without solving core delivery challenges.
- Neutral Agent insists the low upfront signals doubt, while Eastern Agent says it reflects smart risk-adjusted deal structuring for an early-stage asset.
Blind spots
- Neither side fully addresses whether ABA001 can be manufactured cheaply enough to compete with generic hypertension pills like amlodipine.
- Both overlook how China's health insurance system might actually cover the drug, given its focus on cost control over premium novel therapies.
- The debate ignores the possibility that the drug could fail in Phase II, making the entire infrastructure investment a sunk cost.
WorldAttention’s read
This deal is a modest but meaningful step for China's domestic pharma industry, but it's being oversold as a sovereignty triumph. The 50 million yuan upfront is an option fee for an unproven siRNA therapy in a tough disease market. Wanguo's distribution network is valuable, but it only matters if the drug works and can be made cheaply. The real test isn't the deal structure or nationalist framing—it's whether ABA001 can beat existing cheap generics in both efficacy and cost. Until Phase II data comes in, this is a cautious bet, not a victory lap.
Reporting timeline
Sunshine Noah Licenses Hypertension siRNA Drug ABA001 to Wangao Pharma for 50 Million Yuan
Sunshine Noah (688621.SH) announced a partnership with Jiangsu Wangao Pharmaceutical Co., Ltd. for the development and commercialization of ABA001, a novel siRNA drug for hypertension. Wangao will invest 50 million yuan to fund ABA001's domestic clinical trials, R&D optimization, and regulatory filing, securing exclusive commercialization rights in China. ABA001 targets angiotensinogen (AGT) mRNA via RNA interference, aiming to provide long-lasting blood pressure control with potential dosing every three to six months, a significant shift from daily oral medications. The drug is currently in Phase I clinical trials. The deal combines Sunshine Noah's R&D capabilities in small nucleic acid drugs with Wangao's existing cardiovascular product portfolio and commercial infrastructure. The article notes that the AGT-siRNA field is becoming competitive, with several candidates already in Phase II trials, including Alnylam's zilebesiran. The partnership is framed as a risk-sharing arrangement for early-stage development rather than a valuation of the final product, with the drug's true differentiation yet to be proven in clinical trials.
Sunshine Nuohe Signs ABA001 Development Agreement with Wangao Pharmaceutical for Hypertension Drug
On September 21, Sunshine Nuohe (Sunshine Nuohe) announced that it has signed a cooperation agreement with Wangao Pharmaceutical for the joint development of the ABA001 project. According to the agreement, Wangao Pharmaceutical will invest 50 million yuan in this phase, with all funds designated exclusively for the product's domestic clinical trials, R&D optimization, regulatory filing, compliance operations, and other project-related expenses. ABA001 is a self-initiated R&D project by Sunshine Nuohe, primarily targeting hypertension, and is currently in Phase I clinical trials. The announcement was sourced from Jin10 Data.
Read sourceSunshine Novo Signs ABA001 Project Co-Development Agreement with Wan Gao Pharma
Sunshine Novo (688621.SH) announced on September 21 that it has signed an 'ABA001 Project Co-Development Agreement' with Jiangsu Wan Gao Pharmaceutical Co., Ltd. (Wan Gao Pharma). Under the agreement, Wan Gao Pharma will invest 50 million RMB in the current phase, with funds strictly allocated for domestic clinical trials, R&D optimization, regulatory filings, compliance operations, and other project-direct expenses. The partnership aims to jointly develop the ABA001 project, though specific details on the drug candidate or therapeutic area were not disclosed in the announcement.
Read sourceShow 2 older updatesHide older updates
Sunshine Nuohe and Wangao Pharma Sign ABA001 Hypertension Drug Development Deal
Sunshine Nuohe (stock code: 688621) announced on September 21 that it has entered into a cooperation agreement with Wangao Pharmaceutical to jointly develop the ABA001 project. Under the terms of the agreement, Wangao will invest 50 million yuan in the current phase, with all funds designated exclusively for domestic clinical trials, research optimization, regulatory filing, compliance operations, and other directly related project expenses. ABA001 is a drug candidate independently developed by Sunshine Nuohe for the treatment of hypertension. The project is currently in Phase I clinical trials. The announcement was made via a stock exchange filing and reported by People's Financial Information on the same day.
Read sourceSunshine Novo partners with Wanguo Pharma, invests 50 million yuan in ABA001 development
Sunshine Novo (Sunshine Nuohe) announced a partnership with Jiangsu Wanguo Pharmaceutical Co., Ltd. to jointly develop the ABA001 project, signing a cooperation agreement. Under the terms, Wanguo Pharmaceutical will invest 50 million yuan (approximately $7 million) in this phase, with funds allocated exclusively for domestic clinical trials, research optimization, regulatory filing, compliance operations, and other project-related expenses. The ABA001 drug candidate is currently in Phase I clinical trials. The announcement was made via a stock market live feed on Stockstar, a Chinese financial news platform. The partnership represents a significant financial commitment to advance the development of ABA001 through early-stage clinical testing and regulatory processes in China.